Results 51 to 60 of about 2,860,326 (352)

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Nature Reviews Microbiology, 2022
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19 and are especially important in high-risk individuals where vaccination is not an option. Given the importance of understanding the evolution of resistance to mAbs
MacGregor Cox, T. Peacock, William T. Harvey, J. Hughes, Derek W. Wright, B. Willett, E. Thomson, Ravindra K. Gupta, S. Peacock, David L. Robertson, A. Carabelli   +10 more
semanticscholar   +1 more source

Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases

Frontiers in Immunology, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is primarily diagnosed through viral RNA positivity in nasopharyngeal swabs, and it is associated with the early detection of specific immunoglobulins to SARS-CoV-2 proteins.
Martina Ranzenigo, Claudia Pastori, Gabriel Siracusano, Elena Pariani, Caterina Uberti-Foppa, Lucia Lopalco   +5 more
doaj   +1 more source

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

iScience, 2022
Summary: The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and ...
Fangzhu Zhao, Celina Keating, Gabriel Ozorowski, Namir Shaabani, Irene M. Francino-Urdaniz, Shawn Barman, Oliver Limbo, Alison Burns, Panpan Zhou, Michael J. Ricciardi, Jordan Woehl, Quoc Tran, Hannah L. Turner, Linghang Peng, Deli Huang, David Nemazee, Raiees Andrabi, Devin Sok, John R. Teijaro, Timothy A. Whitehead, Andrew B. Ward, Dennis R. Burton, Joseph G. Jardine   +22 more
doaj   +1 more source

How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin

Nature Communications, 2018
Influenza virus can escape most antibodies with single mutations. However, rare antibodies broadly neutralize many viral strains. It is unclear how easily influenza virus might escape such antibodies if there was strong pressure to do so.
Michael B. Doud, Juhye M. Lee, J. Bloom
semanticscholar   +1 more source

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola, Ralph Steinman, Richter C. King, the Working Group convened by the Global HIV Vaccine Enterprise   +3 more
core   +3 more sources

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release

EBioMedicine, 2017
Many broadly reactive human monoclonal antibodies against the hemagglutinin (HA) stem of influenza A virus have been developed for therapeutic applications.
Seiya Yamayoshi, Ryuta Uraki, Mutsumi Ito, Maki Kiso, Sumiho Nakatsu, Atsuhiro Yasuhara, Kohei Oishi, Tadahiro Sasaki, Kazuyoshi Ikuta, Yoshihiro Kawaoka   +9 more
doaj   +1 more source

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. [PDF]

, 2008
Hepatitis C virus (HCV) infection is dependent on at least three coreceptors: CD81, scavenger receptor BI (SR-BI), and claudin-1. The mechanism of how these molecules coordinate HCV entry is unknown.
Balfe, Peter, Bassendine, Margaret F, Drummer, Heidi E, Grove, Joe, McKeating, Jane A, Nielsen, Søren, Zhong, Jin   +6 more
core   +3 more sources

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro

Frontiers in Immunology, 2023
Despite the successful development of vaccines and neutralizing antibodies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerging variants prolong the pandemic and emphasize the persistent need to develop effective ...
Latifa Zekri, Latifa Zekri, Latifa Zekri, Latifa Zekri, Natalia Ruetalo, Mary Christie, Carolin Walker, Carolin Walker, Timo Manz, Timo Manz, Hans-Georg Rammensee, Hans-Georg Rammensee, Hans-Georg Rammensee, Helmut R. Salih, Helmut R. Salih, Helmut R. Salih, Michael Schindler, Gundram Jung, Gundram Jung, Gundram Jung   +19 more
doaj   +1 more source

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge [PDF]

, 2016
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation the liver graft of viremic patients universally becomes infected by circulating virus ...
Baumert, Thomas F., Cole, Sarah, Desombere, Isabelle, Fafi-Kremer, Samira, Farhoudi, Ali, Heydmann, Laura, Leroux-Roels, Geert, McKeating, Jane A., Meuleman, Philip, Patel, Arvind H., Pessaux, Patrick, Van Houtte, Freya, Verhoye, Lieven   +12 more
core   +2 more sources